loading
前日終値:
$119.00
開ける:
$119.52
24時間の取引高:
665.43K
Relative Volume:
0.87
時価総額:
$9.82B
収益:
$51.48M
当期純損益:
$-315.00M
株価収益率:
-33.42
EPS:
-3.5708
ネットキャッシュフロー:
$-244.00M
1週間 パフォーマンス:
+5.14%
1か月 パフォーマンス:
+52.56%
6か月 パフォーマンス:
+59.62%
1年 パフォーマンス:
+163.99%
1日の値動き範囲:
Value
$114.00
$120.60
1週間の範囲:
Value
$111.21
$120.90
52週間の値動き範囲:
Value
$36.65
$130.05

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name
名前
Kymera Therapeutics Inc
Name
セクター
Healthcare (1096)
Name
電話
857-285-5314
Name
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Name
職員
253
Name
Twitter
Name
次回の収益日
2026-08-10
Name
最新のSEC提出書
Name
KYMR's Discussions on Twitter

Compare KYMR vs VRTX, REGN, ARGX, ALNY, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
KYMR icon
KYMR
Kymera Therapeutics Inc
119.35 9.82B 51.48M -315.00M -244.00M -3.5708
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
485.39 123.19B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
664.52 69.67B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
877.62 54.58B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
298.76 39.89B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
186.88 39.73B 742.00K -1.37B -1.07B -7.0731

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-16 再開されました Jefferies Buy
2026-01-28 再開されました Barclays Overweight
2026-01-06 ダウングレード Wolfe Research Outperform → Peer Perform
2025-11-03 再開されました Guggenheim Buy
2025-10-24 繰り返されました B. Riley Securities Buy
2025-10-21 開始されました Mizuho Outperform
2025-09-18 繰り返されました H.C. Wainwright Buy
2025-09-17 開始されました Barclays Overweight
2025-09-16 開始されました RBC Capital Mkts Outperform
2025-07-30 再開されました B. Riley Securities Buy
2025-07-03 再開されました Morgan Stanley Overweight
2025-06-03 アップグレード B. Riley Securities Neutral → Buy
2025-06-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-06-02 アップグレード BofA Securities Neutral → Buy
2025-05-20 再開されました Stifel Buy
2025-03-13 開始されました Citigroup Buy
2024-12-10 開始されました BTIG Research Buy
2024-12-06 開始されました BMO Capital Markets Market Perform
2024-12-02 アップグレード Wells Fargo Equal Weight → Overweight
2024-11-18 開始されました Stephens Overweight
2024-09-09 再開されました Leerink Partners Outperform
2024-08-26 アップグレード Wolfe Research Peer Perform → Outperform
2024-04-22 開始されました Oppenheimer Outperform
2024-02-15 開始されました Wolfe Research Peer Perform
2024-01-04 アップグレード JP Morgan Neutral → Overweight
2024-01-03 ダウングレード BofA Securities Buy → Neutral
2023-12-19 ダウングレード Wells Fargo Overweight → Equal Weight
2023-06-30 開始されました Truist Buy
2023-05-05 アップグレード Raymond James Mkt Perform → Outperform
2022-12-06 ダウングレード Credit Suisse Outperform → Neutral
2022-11-08 開始されました Raymond James Mkt Perform
2022-08-15 開始されました Jefferies Buy
2022-08-03 開始されました Goldman Buy
2022-07-20 開始されました SVB Leerink Mkt Perform
2022-04-28 開始されました Credit Suisse Outperform
2022-03-10 開始されました JP Morgan Neutral
2022-02-10 開始されました Wells Fargo Overweight
2021-09-30 開始されました B. Riley Securities Neutral
2021-09-30 開始されました Stifel Buy
2021-09-10 ダウングレード BofA Securities Buy → Neutral
2021-05-21 開始されました UBS Buy
2021-04-14 開始されました Berenberg Buy
2020-12-04 開始されました H.C. Wainwright Buy
2020-09-15 開始されました BofA Securities Neutral
2020-09-15 開始されました Cowen Outperform
2020-09-15 開始されました Guggenheim Buy
2020-09-15 開始されました Morgan Stanley Equal-Weight
すべてを表示

Kymera Therapeutics Inc (KYMR) 最新ニュース

pulisher
Jul 09, 2026

Strength seen in Kymera Therapeutics (KYMR): Can its 16.6% jump turn into more strength? - MSN

Jul 09, 2026
pulisher
Jul 09, 2026

Is Kymera (KYMR) the Best Performing American Stock in June 2026? - Insider Monkey

Jul 09, 2026
pulisher
Jul 08, 2026

Kymera jumps 17% on early enrollment completion in skin disease study - MSN

Jul 08, 2026
pulisher
Jul 08, 2026

Hedge Fund and Insider Trading News: Bill Ackman, Ken Griffin, Warren Buffett, Ray Dalio, Scion Asset Management, Brevan Howard, Kymera Therapeutics Inc (KYMR), Sony Group Corp (SONY), and More - Insider Monkey

Jul 08, 2026
pulisher
Jul 08, 2026

(KYMR) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Jul 08, 2026
pulisher
Jul 08, 2026

Kymera Therapeutics Insider Sold Shares Worth $5,950,000, According to a Recent SEC Filing - marketscreener.com

Jul 08, 2026
pulisher
Jul 07, 2026

Kymera Therapeutics(KYMR.US) Officer Sells US$5.95 Million in Common Stock - Moomoo

Jul 07, 2026
pulisher
Jul 07, 2026

Form 4 Kymera Therapeutics Inc For: 7 July By Investing.com - Investing.com Nigeria

Jul 07, 2026
pulisher
Jul 07, 2026

Kymera Therapeutics CEO Mainolfi sells $5.95m in stock By Investing.com - Investing.com India

Jul 07, 2026
pulisher
Jul 07, 2026

Kymera Therapeutics CEO Mainolfi sells $5.95m in stock - Investing.com

Jul 07, 2026
pulisher
Jul 07, 2026

Form 144 Kymera Therapeutics For: 7 July By Investing.com - Investing.com Nigeria

Jul 07, 2026
pulisher
Jul 07, 2026

Kymera Therapeutics, Inc. Announces Appointment of Elizabeth Laws as Senior Vice President - marketscreener.com

Jul 07, 2026
pulisher
Jul 07, 2026

Kymera hires ex-Sanofi executive to lead KT-621 development - Investing.com

Jul 07, 2026
pulisher
Jul 07, 2026

Kymera hires ex-Sanofi executive to lead KT-621 development By Investing.com - Investing.com South Africa

Jul 07, 2026
pulisher
Jul 07, 2026

Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader - The Manila Times

Jul 07, 2026
pulisher
Jul 06, 2026

Kymera Therapeutics Insider Sold Shares Worth $8,864,829, According to a Recent SEC Filing - Moomoo

Jul 06, 2026
pulisher
Jul 04, 2026

KYMRKymera Therapeutics Inc Options - Finviz

Jul 04, 2026
pulisher
Jul 03, 2026

Kymera Therapeutics: Why It May Be Time To Jump On The Bandwagon (Upgrade) (NASDAQ:KYMR) - Seeking Alpha

Jul 03, 2026
pulisher
Jul 03, 2026

Kymera: Building Toward A Defining 2H26 Moment (NASDAQ:KYMR) - Seeking Alpha

Jul 03, 2026
pulisher
Jul 03, 2026

Kymera Therapeutics (KYMR) Stock Gets Fair Value Bump After KT 621 Timeline Shift - Yahoo Finance

Jul 03, 2026
pulisher
Jul 02, 2026

Kymera Therapeutics(KYMR.US) Officer Sells US$9.22 Million in Common Stock - Moomoo

Jul 02, 2026
pulisher
Jul 02, 2026

How Accelerated KT-621 Trial, Index Additions, and New Chair Will Impact Kymera Therapeutics (KYMR) Investors - Yahoo Finance

Jul 02, 2026
pulisher
Jul 02, 2026

Insider Sell: Noah Goodman Sells Shares of Kymera Therapeutics I - GuruFocus

Jul 02, 2026
pulisher
Jul 02, 2026

Kymera Therapeutics director Bruce Booth sells $8.28m in shares By Investing.com - Investing.com Australia

Jul 02, 2026
pulisher
Jul 02, 2026

Kymera Therapeutics director Bruce Booth sells $8.28m in shares - Investing.com

Jul 02, 2026
pulisher
Jul 02, 2026

Form 4 Kymera Therapeutics Inc For: 2 July By Investing.com - Investing.com Canada

Jul 02, 2026
pulisher
Jul 02, 2026

Form 144 Kymera Therapeutics For: 2 July By Investing.com - Investing.com Canada

Jul 02, 2026
pulisher
Jul 02, 2026

Kymera Therapeutics (KYMR) Is Up 16.7% After KT-621 Trial Acceleration And Index Additions Has The Bull Case Changed? - Sahm

Jul 02, 2026
pulisher
Jul 01, 2026

KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug - Yahoo Finance

Jul 01, 2026
pulisher
Jul 01, 2026

KYMR Stock Clocks Best Day In Over 6 Months On Advancing Eczema Trial Timeline - Stocktwits

Jul 01, 2026
pulisher
Jun 30, 2026

Kymera Therapeutics director sells $56.5m in shares - Investing.com UK

Jun 30, 2026
pulisher
Jun 30, 2026

Form 4 Kymera Therapeutics Inc For: 30 June By Investing.com - Investing.com Nigeria

Jun 30, 2026
pulisher
Jun 30, 2026

Kymera Therapeutics director sells $56.5m in shares By Investing.com - Investing.com South Africa

Jun 30, 2026
pulisher
Jun 30, 2026

Kymera Therapeutics director Booth sells $3.42 million in KYMR shares - Investing.com

Jun 30, 2026
pulisher
Jun 30, 2026

Kymera Therapeutics director Booth sells $3.42 million in KYMR shares By Investing.com - Investing.com India

Jun 30, 2026
pulisher
Jun 30, 2026

Kymera Therapeutics(KYMR.US) Director Sells US$59.88 Million in Common Stock - Moomoo

Jun 30, 2026
pulisher
Jun 30, 2026

BofA Securities Initiates Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $125 - Moomoo

Jun 30, 2026
pulisher
Jun 30, 2026

BofA Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $125 - Moomoo

Jun 30, 2026
pulisher
Jun 30, 2026

KYMR Maintained by B of A Securities -- Price Target Raised to $125 - GuruFocus

Jun 30, 2026
pulisher
Jun 29, 2026

KYMR Maintained by B. Riley Securities -- Price Target Raised to $155 - GuruFocus

Jun 29, 2026
pulisher
Jun 29, 2026

Form 144 KYMERA THERAPEUTICS For: 29 June By Investing.com - Investing.com Nigeria

Jun 29, 2026
pulisher
Jun 29, 2026

KYMR Maintained by Truist Securities -- Price Target Raised to $136 - GuruFocus

Jun 29, 2026
pulisher
Jun 29, 2026

B. Riley Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $155 - Moomoo

Jun 29, 2026
pulisher
Jun 29, 2026

Kymera Therapeutics, Inc.(NasdaqGM: KYMR) added to Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Truist raises Kymera Therapeutics price target on AD timeline By Investing.com - Investing.com Canada

Jun 29, 2026
pulisher
Jun 29, 2026

B. Riley Adjusts Kymera Therapeutics Price Target to $155 From $117, Maintains Buy Rating - marketscreener.com

Jun 29, 2026

Kymera Therapeutics Inc (KYMR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$56.43
price down icon 2.64%
$115.61
price down icon 2.24%
$35.97
price down icon 2.28%
$68.27
price down icon 10.83%
ONC ONC
$298.70
price down icon 1.36%
$186.88
price down icon 2.22%
大文字化:     |  ボリューム (24 時間):